Eli Lilly and Company– tag –
-
Eli Lilly’s Foundayo (orforglipron) Receives FDA Approval, Ushering in a New Era of Oral GLP-1 RAs for Obesity Treatment
2 Minute Medicine USA Overview On April 1, 2026, Eli Lilly's Foundayo (orforglipron) gained FDA approval for obesity treatment, marking the first non-peptide oral GLP-1 receptor agonist without food or water timing restrictions. This bre... -
Novartis Partners with Chai Discovery to Accelerate Antibody Drug Development using Advanced AI Model Chai-3
Scientist Live USA Overview Novartis has formed a strategic alliance with Chai Discovery to expedite antibody drug development across multiple therapeutic programs, leveraging Chai's advanced AI models, including Chai-3. This collaborati... -
3D Bioprinting Market Projected to Reach $6.21 Billion by 2030 Driven by Personalized Medicine and Organ Demand
The Business Research Company (via OpenPR) Unknown Overview This article provides an overview of a market research report published by The Business Research Company. The 3D bioprinting market is projected to expand to $6.21 billion by 20... -
2026 GLP-1 Agonist Pipeline Highlights Oral Orforglipron Approval and Retatrutide’s >28% Weight Reduction
Drug Discovery News USA Overview The 2026 GLP-1 agonist clinical pipeline is focusing on enhanced weight loss efficacy through novel mechanisms. Notably, Eli Lilly's oral small-molecule GLP-1 receptor agonist, orforglipron, received FDA ... -
First AI-Designed Drug Poised for FDA Approval by 2026-2027: Insilico Medicine’s IPF Candidate Leads
Oncodaily USA Overview The first AI-designed drug is increasingly likely to gain FDA approval between 2026 and 2027, with Insilico Medicine's rentosertib for idiopathic pulmonary fibrosis (IPF) identified as the leading candidate. Eli Li... -
The Rise of Oral GLP-1 Receptor Agonists: Transforming Diabetes and Obesity Treatment Convenience from Injections to Pills
Pharmacy Times USA Overview The advent of oral GLP-1 receptor agonists (GLP-1RAs) is fundamentally transforming drug administration in diabetes and obesity treatment. Oral formulations are rapidly gaining traction in the previously injec... -
GLP-1 Receptor Agonists Expand Therapeutic Scope to MASH: Novo Nordisk’s Wegovy First FDA-Approved for MASH, Eli Lilly’s Oral Foundayo Launched
Drug Discovery Trends USA Overview The therapeutic scope of GLP-1 receptor agonists has expanded beyond diabetes and obesity to include cardiovascular risk, obstructive sleep apnea, chronic kidney disease, and by 2025, MASH (Metabolic Dy... -
FDA Approves, Clears Trials for Autism-Related Symptom Treatments: DeFloria’s AJA001 Oral Liquid Enters Phase 2, Generic Leucovorin Approved
Barchart.com (via DelveInsight) USA Overview The FDA has authorized Phase II clinical trials for DeFloria's AJA001 oral liquid, a plant-derived drug candidate for autism spectrum disorder (ASD)-related symptoms. Additionally, in March 20... -
Biopharma M&A Accelerates in H1 2026: Eli Lilly Leads with Over $25 Billion Spend as Big Pharma Bolsters Pipelines
BioPharma Dive USA Overview Biopharmaceutical M&A activity significantly accelerated in the first half of 2026, with over 50 deals transacted. Eli Lilly was notably active, spending over $25 billion and solidifying its position as a ... -
AI Drug Discovery Investment Surges to $10 Billion in 2026 with Eli Lilly Partnerships and Over 173 Clinical Programs, Highlighting Isomorphic Labs
MarketWise USA Overview Investment in AI drug discovery is booming in 2026, following Anthropic's CEO's prediction of a biotech renaissance, with AI and ML-related biopharma deals already nearing $10 billion. Key drivers include Eli Lill...
